Ketamine Therapy for Post-Traumatic Stress Disorder A Structured Evidence Synthesis of Randomized Trials and Systematic Reviews Through August 2026
Study at a glance
AI-extracted from the abstract| Characteristics | White paper synthesizing a curated evidence dataset Randomized |
|---|---|
| Sample size | 158 |
| Population | Patients with established or comorbid PTSD, plus prevention studies in acute trauma or intensive-care populations |
| Interventions | Ketamine Esketamine |
| Dose | 0.2 or 0.5 mg/kg intravenous ketamine |
| Topics | Esketamine Ketamine PTSD |
| Key points | The authors conclude that ketamine can produce rapid clinically meaningful improvement in a subset of PTSD patients, but magnitude, reproducibility, durability, optimal regimen, and patient selection remain unresolved. The largest multicenter randomized trial (N=158) found no significant PTSD advantage for 0.2 or 0.5 mg/kg intravenous ketamine over saline despite eight infusions, and small-study-bias correction reduced the pooled effect to a small, statistically uncertain advantage. |
Abstract
Ketamine has emerged as a plausible rapid-acting treatment for post-traumatic stress disorder (PTSD), but the clinical literature is unusually easy to overstate because a small number of randomized trials are repeatedly represented across reviews, several publications reuse the same cohorts, and treatment studies are sometimes mixed with PTSD-prevention studies conducted around acute trauma. This white paper synthesizes a curated evidence dataset updated through August 18, 2026, containing 21 systematic reviews/meta-analyses and 10 published randomized PTSD-outcome reports. The 10 randomized reports represent approximately nine independent trial families; eight reports address established or comorbid PTSD and two address prevention or later PTSD outcomes after acute trauma or intensive-care treatment. Among approximately seven independent treatment trial families, several small studies found rapid and sometimes large symptom reductions, including a 2014 single-infusion trial, a 2021 repeated-infusion trial, and a 2025 intramuscular crossover trial. However, the largest multicenter randomized study (N=158) found no significant PTSD advantage for either 0.2 or 0.5 mg/kg intravenous ketamine over saline despite eight infusions. Meta-analytic results therefore depend heavily on method: pooled estimates often favor ketamine, but the most explicit small-study-bias correction reduced the overall effect to a small, statistically uncertain advantage. The strongest supported conclusion is not that ketamine reliably treats PTSD, nor that it is ineffective. Rather, ketamine can produce rapid clinically meaningful improvement in a subset of patients, but the magnitude, reproducibility, durability, optimal regimen, and patient-selection rules remain unresolved. Evidence is stronger for a rapid signal than for durable remission, stronger for racemic ketamine than for esketamine, and insufficient to establish a specific added benefit from ketamine-assisted psychotherapy. The evidence threshold for routine first-line use has not been met, while the evidence is substantial enough to justify continued controlled study and specialist off-label consideration in carefully selected treatment-resistant cases.